Open for inclusion

Durvalumab (MEDI4736) After chemoRadioTherapy (DART) for NSCLC patients – a phase II translational and biomarker study investigating PDL1 positive and negative patients

Cancer type: Lung cancer

Phase: II

Principal Investigator: Helland Åslaug

Country: NO

Keywords: Norway, Oslo, lung, durvalumab, DART

Status: Open for inclusion

Link to Clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT04392505